Compare BTO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTO | CSTL |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.2M | 661.7M |
| IPO Year | N/A | 2019 |
| Metric | BTO | CSTL |
|---|---|---|
| Price | $35.27 | $38.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $38.67 |
| AVG Volume (30 Days) | 54.2K | ★ 439.7K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 9.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $343,530,000.00 |
| Revenue This Year | N/A | $1.69 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $22.95 | $14.59 |
| 52 Week High | $32.81 | $40.61 |
| Indicator | BTO | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 63.04 | 71.92 |
| Support Level | $34.09 | $38.69 |
| Resistance Level | $34.75 | $40.54 |
| Average True Range (ATR) | 0.72 | 1.58 |
| MACD | 0.31 | -0.18 |
| Stochastic Oscillator | 93.17 | 75.59 |
John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.